Breaking News
Upgrade 0
🚀 5 new AI-picked strategies for US stocks beating the market in healthcare, energy & more
Learn more
Close

Arbutus Biopharma Corp (ABUS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arbutus Biopharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.410 -0.100    -2.22%
20:59:59 - Closed. Currency in USD
After Hours
4.602
+0.192
+4.354%
22:35:32 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 805,860
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.355 - 4.580
Arbutus Biopharma 4.410 -0.100 -2.22%

Arbutus Biopharma Corp Company Profile

 
Get an in-depth profile of Arbutus Biopharma Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

44

Equity Type

ORD

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Contact Information

Address 701 Veterans Circle
Warminster, 18974
United States
Phone 267 469 0914
Fax -

Top Executives

Name Age Since Title
Lindsay Androski 52 2025 Interim President, CEO & Director
William T. Symonds 57 2015 Chairman of Scientific Advisory Board
Joseph Bishop - 2025 Director
Robert Alan Beardsley 63 2025 Independent Director
Matthew Gline 41 2025 Independent Director
Roger A. Sawhney 55 2025 Director
Jordan J. Feld - 2025 Member of Scientific Advisory Board
Mark Sulkowski - 2025 Member of Scientific Advisory Board
Man-Fung Yuen - 2025 Member of Scientific Advisory Board
Edward J. Gane - 2025 Member of Scientific Advisory Board
Anna Suk-fong Lok - 2025 Member of Scientific Advisory Board
Harry Janssen - 2025 Member of Scientific Advisory Board
Ulrike Protzer - - Member of Scientific Advisory Board
Charles M. Rice - - Member of Scientific Advisory Board
Scott A. Biller 69 - Member of Scientific Advisory Board
Kyong-Mi Chang - - Member of Scientific Advisory Board
Fabien Zoulim - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABUS Comments

Write your thoughts about Arbutus Biopharma Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email